AR063606A1 - Estabilizacion de vacunas mediante liofilizacion - Google Patents

Estabilizacion de vacunas mediante liofilizacion

Info

Publication number
AR063606A1
AR063606A1 ARP070104963A AR063606A1 AR 063606 A1 AR063606 A1 AR 063606A1 AR P070104963 A ARP070104963 A AR P070104963A AR 063606 A1 AR063606 A1 AR 063606A1
Authority
AR
Argentina
Prior art keywords
liofilization
vaccine
stabilization
vaccine stabilization
compositions
Prior art date
Application number
Other languages
English (en)
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365126&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063606(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of AR063606A1 publication Critical patent/AR063606A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas, por ejemplo vacunas, y métodos de elaboración y uso de estas composiciones. Reivindicación 1: Una composición comprende una vacuna de flavivirus vivos, atenuados, uno o más estabilizadores, uno o más agentes de relleno y uno o más componentes amortiguadores del pH.
ARP070104963 2006-11-07 2007-11-07 Estabilizacion de vacunas mediante liofilizacion AR063606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85742406P 2006-11-07 2006-11-07

Publications (1)

Publication Number Publication Date
AR063606A1 true AR063606A1 (es) 2009-02-04

Family

ID=39365126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104963 AR063606A1 (es) 2006-11-07 2007-11-07 Estabilizacion de vacunas mediante liofilizacion

Country Status (15)

Country Link
US (1) US9132184B2 (es)
EP (3) EP2851087B1 (es)
JP (1) JP5687836B2 (es)
CN (2) CN101808657A (es)
AR (1) AR063606A1 (es)
AU (1) AU2007317847B2 (es)
BR (1) BRPI0718548A2 (es)
CA (1) CA2668834C (es)
CL (1) CL2007003209A1 (es)
HK (1) HK1210410A1 (es)
IL (1) IL198563A0 (es)
MX (1) MX2009004862A (es)
RU (1) RU2541784C2 (es)
TW (1) TWI417113B (es)
WO (1) WO2008057550A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063606A1 (es) 2006-11-07 2009-02-04 Acambis Inc Estabilizacion de vacunas mediante liofilizacion
NO2198007T3 (es) 2007-09-14 2018-03-24
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) * 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
SG175916A1 (en) * 2009-04-08 2011-12-29 Eu Yan Sang Internat Ltd Uses of red yeast rice in treating dengue virus infection
CN102260351A (zh) * 2010-05-25 2011-11-30 吉林圣元科技有限责任公司 流感病毒M2e蛋白的制备及其在抗甲型流感病毒中的应用
JP6034798B2 (ja) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
JP6034797B2 (ja) * 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 凍結乾燥されたウイルス製剤
PL3150222T3 (pl) * 2010-12-22 2020-05-18 Wyeth Llc Stabilne immunogenne kompozycje antygenów staphylococcus aureus
DK2741740T3 (en) * 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
CA2859916C (en) 2012-01-09 2021-02-09 Sanofi Pasteur Biologics, Llc Purification of herpes virus
EP2852662B1 (en) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
NZ631012A (en) 2013-03-14 2017-08-25 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
US11123420B2 (en) * 2015-09-30 2021-09-21 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
RU2637634C1 (ru) * 2016-10-21 2017-12-05 Владимир Иосифович Лозинский Антибактериальная белковая губка для химиотерапии инфицированных ран и способ ее получения
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
IL86180A (en) 1987-05-04 1992-08-18 Merck & Co Inc Stable lyophilized live herpes virus vaccine and such a vaccine combined with other virus vaccines
FR2633518B1 (fr) 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6676936B1 (en) 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
JPH09504429A (ja) 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US20050096288A1 (en) * 1997-06-13 2005-05-05 Aragene, Inc. Lipoproteins as nucleic acid vectors
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ATE314476T1 (de) 1997-10-08 2006-01-15 Us Gov Health & Human Serv Chimärer impfstoff gegen das zeckenenzephalitis virus
CN1053590C (zh) * 1998-10-19 2000-06-21 ***长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CN1062770C (zh) * 1998-11-12 2001-03-07 ***长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CN101810854A (zh) * 1999-02-22 2010-08-25 巴克斯特国际公司 新的无白蛋白的因子viii制剂
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
US6589531B1 (en) 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
ES2374131T3 (es) * 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
GB2372991B (en) 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
CN102409063A (zh) * 2001-12-04 2012-04-11 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
AU2003205169A1 (en) * 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
BR122018075729B8 (pt) 2002-01-15 2021-07-27 Acambis Inc flavivírus na preparação de uma composição de vacina
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
WO2003066088A2 (de) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Protease-screening und neue verwendung von proteasen
CA2482448C (en) * 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
ES2337893T3 (es) 2002-11-15 2010-04-30 Sanofi Pasteur Biologics Co. Vacuna del virus del nilo occidental.
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
WO2005089712A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060167022A1 (en) * 2004-09-08 2006-07-27 Woodward John R Method of female sexual enhancement
US8029802B2 (en) 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
US7749734B2 (en) 2004-12-24 2010-07-06 The Research Foundation For Microbial Diseases Of Osaka University Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
AR063606A1 (es) 2006-11-07 2009-02-04 Acambis Inc Estabilizacion de vacunas mediante liofilizacion

Also Published As

Publication number Publication date
RU2541784C2 (ru) 2015-02-20
RU2009121566A (ru) 2010-12-20
CN106890144A (zh) 2017-06-27
EP2086581A2 (en) 2009-08-12
US9132184B2 (en) 2015-09-15
EP2851087B1 (en) 2017-04-19
BRPI0718548A2 (pt) 2013-11-12
JP2010509226A (ja) 2010-03-25
EP2535058A2 (en) 2012-12-19
US20100247573A1 (en) 2010-09-30
EP2086581A4 (en) 2010-05-05
IL198563A0 (en) 2011-08-01
WO2008057550A3 (en) 2009-04-02
HK1210410A1 (en) 2016-04-22
EP2535058A3 (en) 2013-04-10
TW200831132A (en) 2008-08-01
AU2007317847B2 (en) 2013-10-31
CA2668834C (en) 2016-10-11
JP5687836B2 (ja) 2015-03-25
AU2007317847A1 (en) 2008-05-15
TWI417113B (zh) 2013-12-01
CN101808657A (zh) 2010-08-18
EP2086581B1 (en) 2014-08-13
CA2668834A1 (en) 2008-05-15
EP2851087A1 (en) 2015-03-25
WO2008057550A2 (en) 2008-05-15
CL2007003209A1 (es) 2008-05-09
AU2007317847A8 (en) 2009-07-30
MX2009004862A (es) 2009-07-17

Similar Documents

Publication Publication Date Title
AR063606A1 (es) Estabilizacion de vacunas mediante liofilizacion
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
CO6160335A2 (es) Vacuna
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
DK1954308T3 (da) Stabiliseringsmidler til frysetørrede vacciner
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
EA201070066A1 (ru) Вакцины против гриппа с низким содержанием добавок
CL2011002426A1 (es) Compuestos derivados de benzo-diazol pirrolidina sustituidos, inhibidores de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica; y su uso para el tratamiento de una infeccion por vhc.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
BRPI0915813A2 (pt) estabilizante e composição de vacina compreendendo um ou mais flavivírus atenuados vivos
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
CL2008003848A1 (es) Compuestos derivados de fenilo o heteroarilo bis-sulfonilamino sustituidos, inhibidores de prostaglandina e sintasa-1 microsomal; composicion farmaceutica; procedimiento de preparacion; procedimiento de preparacion de la composicion farmaceutica; y uso en el tratamiento del dolor agudo o cronico, dolor nociceptivo o dolor neuropatico.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
NO20084852L (no) MGLUR5 modulatorer V
DK1810676T3 (da) Levetiracetam formuleringer og fremgangsmåder til deres fremstilling
MX2009006178A (es) Vacuna contra salmonela.
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
CL2011003043A1 (es) Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
CO6331444A2 (es) Vacuna contra el virus del nilo occidental

Legal Events

Date Code Title Description
FA Abandonment or withdrawal